Last week JMP Securities analyst Sam Wilson said financial engineering might be on the table for Motorola, and the company could conduct surgery before that recovery comes.
Because there is no scientific evidence to support allegations about negative effects of genetic engineering, they are pounding the table, resorting to scare tactics and specious assertions.